GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution

Human Reproduction

Volumn 21, Issue 10, 2006, Pages 2580-2582

  Lambalk, Cornelis B ^a   Homburg, Roy ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Corpus luteum function; Embryo developmental potential; GnRH agonist; GnRH antagonist; Luteal phase support

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE; TRIPTORELIN;

BIRTH RATE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORPUS LUTEUM; DRUG INDICATION; DRUG SAFETY; EMBRYOTOXICITY; ENDOMETRIUM; FERTILIZATION IN VITRO; FOLLITROPIN RELEASE; GONAD FUNCTION; HORMONAL THERAPY; HUMAN; INTRAUTERINE INSEMINATION; LUTEAL PHASE; LUTEINIZATION; LUTEINIZING HORMONE RELEASE; NIDATION; NOTE; OOCYTE DONATION; OOCYTE MATURATION; OUTCOME ASSESSMENT; OVULATION INDUCTION; PREGNANCY RATE; SINGLE DRUG DOSE;

EID: 33749592772     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del321     Document Type: Note

References (26)

1. Albano C, Camus M, Rietmuller-Winzen H, van Steirtigem A and Devroey P (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67,917-922.
2. Balasch J, Martinez F, Jové I, Cabré L, Coroleu B, Barri PN and Vanrell JA (1993) Inadvertent honadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod 8,1148-1151.
3. Elefant E, Biour B, Blumberg-Tick J, Roux C and Thomas F (1993) Administration of a gonadotropin-releasing hormone agonist during pregnancy: Follow-up of 28 pregnancies exposed to triptoreline. Fertil Steril 63,1111-1113.
4. Fleming R, Adam AH, Barlow DH, Black WP, Macnaughton MC and Coutts JRT (1982) A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol 89,80-83.
5. Fleming R, Haxton MJ, Hamilton MP, McCune GS, Black WP, MacNaughton and Coutts JR (1985) Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins. Br J Obstet Gynaecol 92,369-373.
6. The Ganirelix Dose-Finding Study Group (1998) A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13,3023-3031.
7. Gartner B, Moreno C, Marinaro A, Remohi J, Simon C and Pellicer A (1997) Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod 12,2557-2559.
8. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y and Caspi E (1990) Fetal outcome following inadvertent administration of long-acting D-Trp6 LH-RH microcapsules during pregnancy: A case report. Hum Reprod 5,123-124.
9. Har-Toov J, Brenner SH, Jaffa A, Yavetz H, Peyser MR and Lessing JB (1993) Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause. Fertil Steril 59,446-447.
10. Hughes EG, Fedorkow DM, Daya S, Sagle MA, van de Koppel P and Collins JA (1992) The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomised controlled trials. Fertil Steril 58,888-896.
11. Hugues JN, Cedrin-Durnerin I, Bstandig B, Theron-Gerard L, Grange D, Clement P, Hamidi J, Sifer C and Poncelet C (2006) Administration of gonadotropin-releasing hormone agonist during the luteal phase of the GnRH-antagonist IVF cycles. Hum Reprod 21(Suppl 1), In Abstractbook of 22nd annual Meeting of the Society of Human Reproduction and Embryology, Prague, p. i5 [Abstract 0-007].
12. Huirne JA, van Loenen AC, Schats R, McDonell J, Schoemaker J, Homburg R and Lambalk CB (2004) Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: Antide and hormone levels. Hum Reprod 19,2206-2215.
13. Isherwood PJ, Ibrahim ZA, Matson PL, Morroll DR, Burslem RW and Lieberman BA (1990) Endocrine changes in women conceiving during treatment with a LHRH agonist. Hum Reprod 5,409-412.
14. Jackson AE, Curtis P, Amso N and Shaw RW (1992) Exposure to LHRH agonist in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation. Hum Reprod 7,465-468.
15. Janssens RMJ, Lambalk CB, Vermeiden JPW, Schats R, Bernards JM, Rekers-Mombarg LTM and Schoemaker J (2000) Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 15,2333-2340.
16. Macklon NS and Fauser BCJM (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55,101-108.
17. Pirard C, Donnez J and Loumaye E (2005) GnRH agonist as novel luteal support: Results of a randomised, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 20,1798-1804.
18. Pirard C, Donnez J and Loumaye E (2006) GnRH agonist as luteal phase support in assisted reproduction technique cycles, results of a pilot study. Hum Reprod 21,1894-1900.
19. Porter RN, Smith W, Craft IL, Abdulwahid NA and Jacobs HS (1984) Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet 2,1284-1285.
20. Ron-El R, Golan A, Herman A, Raziel A, Soffer Y and Caspi E (1990) Midluteal gonadotropin-releasing hormone analog administration in early pregnancy. Fertil Steril 53,572-574.
21. Smitz J, Camus M, Devroey P, Bollen N, Toumaye H and Van Steirteghem AC (1991) The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 6,290-293.
22. Tesarik J, Hazout A and Mendoza C (2004) Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 19,1176-1180.
23. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N and Mendoza C (2006) Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-using ovarian stimulation cycles. Hum Reprod 2006 August 22nd [Epub ahead of print].
24. Weissman A and Shoham Z (1993) Favourable pregnancy outcome after administration of a long-acting gonadotropin-releasing hormone agonist in the mid-luteal phase. Hum Reprod 8,496-497.
25. Wilshire GB, Emmi AM, Gagliardi CC and Weiss G (1993) Gonadotropin-releasing hormone agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 60,980-983.
26. Young DC, Snabes MC and Poindexter AN (1993) GnRH agonist exposure during the first trimester of pregnancy. Obstet Gynecol 81,587-589.